|
 Edward is managing partner of BioGeneration Ventures,
an
investment fund that focuses on early stage
companies in
the life sciences. During his career he has gained
experience in both small and big pharmaceutical
companies.
Edward was trained as biochemist and biochemical
engineer. After spending some time as research fellow
at
the Pasteur Institute in Paris, he decided he wanted to
work in the biotech industry. In 1993 he could start at EuroCetus (later Chiron), Amsterdam as a process
engineer and later moved to Janssen Pharmaceutica in
Belgium.
At Janssen he started as project engineer in
the production facilities of Janssen but quickly was
able to transfer to the R&D organization of
Johnson &
Johnson and became responsible as project manager in the
oncology franchise.
In 2000 a Dutch entrepreneur convinced him to start as
director business development at Pepscan Systems where
he learned all aspects of working in an early stage
company. In 2003 Edward became CEO of Macrozyme. Under
his responsibility Macrozyme was able to develop a new
drug for the treatment of Type II Diabetes and to
license this program to a large US-based biotech company
in 2005. Edward’s combination of experience in the
development of new technologies and innovative medicines
and the route to commercialization is exactly what he is
confronted with at BioGeneration Ventures on an every
day basis.
|
